New SPRAVATO (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting
Johnson & Johnson presents findings from the largest European real-world dataset for…
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator…
